Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - Anthera Pharmaceuticals Inc | f58159exv99w1.htm |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 1, 2011
ANTHERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-34637 | 20-1852016 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification No.) |
25801 Industrial Boulevard, Suite B, Hayward, California | 94545 | |
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (510) 856-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. |
(c) Effective February 1, 2011, A. Rachel Leheny, Ph.D., a member of the Board of Directors (the
Board) of Anthera Pharmaceuticals, Inc. (the Company), resigned from her position as a Class II
member of the Board.
(d) On the same date, the Board appointed Peter Thompson, M.D., to serve on the Board as a Class II
director and to fill the vacancy created by Dr. Lehenys resignation.
As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange
Commission on September 22, 2010, Dr. Thompson is currently a Venture Partner with OrbiMed
Advisors, LLC and has over 20 years of industry experience. He co-founded Trubion Pharmaceuticals,
and served as CEO and Chairman from its inception through its IPO on NASDAQ and as a public company
until his retirement in 2009. Dr. Thompson is the former Vice President and General Manager of
Chiron Informatics at Chiron Corporation and held various executive positions at Becton Dickinson,
including Vice President, Research and Technology Department of BD Bioscience. Dr. Thompson is a
co-founder of iMetrikus, a clinical decision support company, where he served as CEO and Chairman.
He is the founder and Managing Director of Strategicon Partners, an investment and management
services company. He serves as a Director of Response Biomedical and CoDa Therapeutics. Dr.
Thompson is an Ernst & Young Entrepreneur of the Year awardee, an inventor on numerous patents, a
board-certified internist and oncologist, and was on staff at the National Cancer Institute
following his internal medicine training at Yale University. A copy of the press release
announcing Dr. Thompsons appointment is filed herewith as Exhibit 99.1
(e) In addition, effective February 1, 2011, the Companys Board, upon the recommendation of the
Compensation Committee of the Board, approved annual base salary adjustments for certain of the
Companys employees, including certain of the Companys named executive officers as part of its
annual review of compensation. The adjusted salaries for such named executive officers are as
follows:
Annual Base Salary | ||||||||
Named Executive Officer | Current Annual Base Salary | Effective February 1, 2011 | ||||||
Paul F. Truex, |
$ | 425,000 | $ | 500,000 | ||||
President and Chief
Executive Officer |
||||||||
Christopher P. Lowe, |
$ | 300,000 | $ | 340,000 | ||||
Vice President of
Administration and
Chief Business Officer |
||||||||
Colin Hislop, M.D., |
$ | 320,000 | $ | 340,000 | ||||
Senior Vice President
and Chief Medical
Officer |
||||||||
Debra Odink, Ph.D., |
$ | 250,000 | $ | 270,000 | ||||
Senior Vice President,
Pharmaceutical
Research and
Development |
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description | |||
99.1 | Press Release, dated February 1, 2011 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 1, 2011 | Anthera Pharmaceuticals, Inc. |
|||
By: | /s/ Christopher P. Lowe | |||
Christopher P. Lowe | ||||
Vice President of Administration and Chief Business Officer |
||||
Exhibit Index
Exhibit No. | Description | |||
99.1 | Press Release, dated February 1, 2011 |